why choose us

First received: July 06, 2023

Clinical Trial: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Triple Negative Breast Cancer (TNBC)

Study Type: INTERVENTIONAL


Official Title: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer

Brief Summary: This clinical trial aims to evaluate the efficacy, safety, and exploratory measures of liposomal doxorubicin and carboplatin combination therapy in the adjuvant setting for early stage triple negative breast cancer (TNBC) patients.The primary objective is to determine the effectiveness of liposomal doxorubicin and carboplatin in reducing the risk of recurrence for early stage TNBC patients.The secondary objectives involve characterizing the safety and toxicity profile of the combination therapy.Adverse events…

Read more